Cardinal Health recently released its latest fiscal results, and the outlook remains bright. While the company saw a minor miss in revenue for the quarter ending June 30, the firm surpassed adjusted earnings expectations significantly. Revenue grew to over 63 billion dollars, driven by demand in specialty pharmaceuticals and core distribution operations.
The company is moving beyond its traditional role as a drug distributor. Expansion into direct-to-patient services and specialty medical practice management is creating higher margins. These moves demonstrate an ability to translate steady volume into faster profit growth. This shift provides a stable counterweight to our technology holdings, offering diversification within the broader healthcare sector.
Management provided full-year guidance for fiscal 2027 that beats current market estimates. The company expects adjusted earnings growth in the range of 13% to 15%. This target is supported by clear performance in its pharmaceutical and specialty segments despite price headwinds from government regulations.
Given the strong operational efficiency and future cash flow projections, the price target on the stock is increasing to 265 dollars. The company continues to prioritize profitability and market position, making it a key component of our current portfolio strategy.